BIO 300
The efficacy of BIO 300 as a MCM was discovered and initially developed by the Department of Defense (DoD) and the National Institutes of Health. Humanetics has successfully opened a new Investigational New Drug application (IND 74460) with FDA to develop BIO 300 for ARS. In addition, BIO 300 has been granted an Orphan Drug Designation for the Prevention of Acute Radiation Syndrome. BIO 300 will be self-administered by war fighters going into harm's way. It also holds promise as a drug for use by first responders and civilians who face the threat of radiation exposure from a nuclear accident or terrorist threat.
Availability: In Development
| Manufacturer |
| Humanetics Corporation |
| Product Name |
| BIO 300 |
| Detection Category |
| Radiological/Nuclear |
| Detection Method |
| Medical Countermeasure; |
| Application |
| Personal Protective Equipment; |
| Equipment Type |
| PPE |
| Product Synopsis |
| The efficacy of BIO 300 as a MCM was discovered and initially developed by the Department of Defense (DoD) and the National Institutes of Health. Humanetics has successfully opened a new Investigational New Drug application (IND 74460) with FDA to develop BIO 300 for ARS. In addition, BIO 300 has been granted an Orphan Drug Designation for the Prevention of Acute Radiation Syndrome. BIO 300 will be self-administered by war fighters going into harm's way. It also holds promise as a drug for use by first responders and civilians who face the threat of radiation exposure from a nuclear accident or terrorist threat. |
| Availability |
| In Development |
| Technology Readiness Level (TRL) |
| 6 |
| User Feedback Sources |
| Indifferent/No user feedback |
| Transportability |
| Pocket Size |
| Live Agent Tested |
| Yes |
| Operating Time |
| Immediate post-exposure use |
| Training Required |
| <1 hour training |
| Manuals Available |
| Yes |
